Sunitinib Enables a Clinical and Pathological Complete Remission of Metastatic Renal Cell Carcinoma (mRCC)

Renal cell carcinoma (RCC) is the most common renal cancer, and has a poor prognosis in individuals with metastases (mRCC). In this report, we describe a 48-year-old woman with unresectable multiple liver metastases and a colonic metastasis of RCC who was treated with sunitinib in combination with h...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Bo, Gong, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5385577/
https://www.ncbi.nlm.nih.gov/pubmed/28409120
http://dx.doi.org/10.1016/j.eucr.2016.11.024
_version_ 1782520627530301440
author Peng, Bo
Gong, Jin
author_facet Peng, Bo
Gong, Jin
author_sort Peng, Bo
collection PubMed
description Renal cell carcinoma (RCC) is the most common renal cancer, and has a poor prognosis in individuals with metastases (mRCC). In this report, we describe a 48-year-old woman with unresectable multiple liver metastases and a colonic metastasis of RCC who was treated with sunitinib in combination with hepatic microwave ablation and obtained a clinical and pathological complete remission. We consider that sunitinib combined with microwave ablation can prevent unresectable hepatic metastases of RCC from evolving, and that sunitinib alone can achieve clinical and pathological remission in patients with colonic metastasis of RCC.
format Online
Article
Text
id pubmed-5385577
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-53855772017-04-13 Sunitinib Enables a Clinical and Pathological Complete Remission of Metastatic Renal Cell Carcinoma (mRCC) Peng, Bo Gong, Jin Urol Case Rep Oncology Renal cell carcinoma (RCC) is the most common renal cancer, and has a poor prognosis in individuals with metastases (mRCC). In this report, we describe a 48-year-old woman with unresectable multiple liver metastases and a colonic metastasis of RCC who was treated with sunitinib in combination with hepatic microwave ablation and obtained a clinical and pathological complete remission. We consider that sunitinib combined with microwave ablation can prevent unresectable hepatic metastases of RCC from evolving, and that sunitinib alone can achieve clinical and pathological remission in patients with colonic metastasis of RCC. Elsevier 2017-04-04 /pmc/articles/PMC5385577/ /pubmed/28409120 http://dx.doi.org/10.1016/j.eucr.2016.11.024 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Oncology
Peng, Bo
Gong, Jin
Sunitinib Enables a Clinical and Pathological Complete Remission of Metastatic Renal Cell Carcinoma (mRCC)
title Sunitinib Enables a Clinical and Pathological Complete Remission of Metastatic Renal Cell Carcinoma (mRCC)
title_full Sunitinib Enables a Clinical and Pathological Complete Remission of Metastatic Renal Cell Carcinoma (mRCC)
title_fullStr Sunitinib Enables a Clinical and Pathological Complete Remission of Metastatic Renal Cell Carcinoma (mRCC)
title_full_unstemmed Sunitinib Enables a Clinical and Pathological Complete Remission of Metastatic Renal Cell Carcinoma (mRCC)
title_short Sunitinib Enables a Clinical and Pathological Complete Remission of Metastatic Renal Cell Carcinoma (mRCC)
title_sort sunitinib enables a clinical and pathological complete remission of metastatic renal cell carcinoma (mrcc)
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5385577/
https://www.ncbi.nlm.nih.gov/pubmed/28409120
http://dx.doi.org/10.1016/j.eucr.2016.11.024
work_keys_str_mv AT pengbo sunitinibenablesaclinicalandpathologicalcompleteremissionofmetastaticrenalcellcarcinomamrcc
AT gongjin sunitinibenablesaclinicalandpathologicalcompleteremissionofmetastaticrenalcellcarcinomamrcc

Ejemplares similares